Results for “therapy”

Determines whether to add a mineralocorticoid receptor antagonist (e.g., spironolactone or eplerenone) to glucocorticoid therapy in glucocorticoid-remediable aldosteronism when blood pressure fails to normalize with glucocorticoid alone. Triggered by persistent hypertension or inadequate BP control despite optimized glucocorticoid dosing in GRA patients.

Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation.

Determines whether to recommend unilateral laparoscopic adrenalectomy or medical therapy with a mineralocorticoid receptor antagonist for patients with confirmed unilateral PA (aldosterone-producing adenoma or unilateral adrenal hyperplasia). Triggered when discussing treatment options after confirming unilateral PA in a hypertensive patient with hypokalemia or resistant hypertension.

Identifies patients with normokalemia and no adrenal tumors on CT who likely have bilateral PA and may proceed directly to medical therapy without AVS. Triggers include when a clinician notes normokalemia and clean adrenal CT and asks 'Is AVS necessary if I suspect bilateral disease?'

Suggests a 3- to 6‑month trial of testosterone dosing to achieve a mid‑normal premenopausal value in a reference assay for postmenopausal women with properly diagnosed HSDD and no contraindications. Triggered when a postmenopausal woman requests therapy for low sexual desire after appropriate HSDD workup and exclusion of contraindications.

Perform digital rectal examination (DRE) in all men before initiating testosterone therapy to exclude prostate abnormalities or support suspicion of hypogonadism when prostate volume is reduced. Triggered when a clinician considers starting testosterone and questions whether a prostate exam is needed first or whether to check the prostate before prescribing TTh.

Analyzing session replays, extracting persona-based behavioral patterns, and storytelling UX issues. Reads the 'why' from real user operation logs. Works with Field/Echo for persona validation.

郭靖（武侠虚构）认知与表达框架（压缩蒸馏）：钝感大智、朴素正义、师徒传承… 触发：射雕英雄传 等。虚构

Create care plans with assessments and interventions. TRIGGERS - Use when user needs help with care-plan related tasks.

Create patient intake forms with history and screening. TRIGGERS - Use when user needs help with intake-form related tasks.

Determines whether to recommend adrenalectomy or mineralocorticoid receptor antagonists for primary aldosteronism based on PA subtype and patient/surgical factors. Triggered after subtype confirmation when clinicians ask “Should this patient have surgery or medical treatment?” or discuss treatment options with the patient.

Econometrics skill for Difference-in-Differences (DID) analysis. Activates when the user asks about: "difference in differences", "DID", "DiD", "diff-in-diff", "parallel trends", "treatment group", "control group", "pre-treatment", "post-treatment", "policy evaluation", "natural experiment", "staggered DID", "event study regression", "two-way fixed effects DID", "callaway santanna", "sun and abraham", "双重差分", "倍差法", "平行趋势", "处理组", "对照组", "政策评估", "事件研究", "交错DID", "渐进处理"

舒淇（演员）认知与表达框架（压缩蒸馏）：性感与文艺并置、自嘲大嘴、慢热真诚 触发：文艺片、松弛感 等。非替本人编造

朴树（音乐人）认知与表达框架（压缩蒸馏）：内向真诚、少话多留白、生命与创作一体… 触发：平凡之路 等。不消费抑郁；非医疗建议

A reflective tarot draw for emotional support (presence-first, non-clinical, non-predictive).

Create patient intake forms with history and screening. TRIGGERS - Use when user needs help with intake-form related tasks.

利威尔（少年漫）认知与表达框架（压缩蒸馏）：兵长洁癖战力、矮个子反差、残酷抉择 触发：进击的巨人 等。虚构；非仇恨教唆

Autonomous error recovery — detect failures, diagnose root cause, apply fixes, and resume without stopping

当在个人发展的某个领域（心智、身体、精神、职业）达到“失调阶段”（即对现状感到厌倦、停滞或不满，但尚未麻木）时，用于主动进入一个能加速学习和成长的“心流”或“痴迷”状态（即“渠道”）

蔡澜（美食 / 生活家）认知与表达框架（压缩蒸馏）：享乐主义正当化、旅行搭子叙事 触发：食神专栏 等。非过量饮酒医疗建议

Create care plans with assessments and interventions. TRIGGERS - Use when user needs help with care-plan related tasks.

当个人或团队因拖延、分心或动力不足，导致重要目标长期停滞不前，需要一种强制机制来激发高度专注和行动力时

Teaches AI patients about stress-dosing and emergency glucocorticoid administration; instructs to obtain emergency card/bracelet/necklace and kit with injectable high-dose GC. Triggers when counseling any patient with adrenal insufficiency (e.g., "Use when counseling patient with adrenal insufficiency...").

Personal trainer operations: client check-ins, workout-program delivery, progress reminders, session reminders, lead follow-up, and workout tracking. Use when an owner is a coach/personal trainer or when managing fitness clients and training routines.

Recommends mineralocorticoid receptor antagonists for all primary aldosteronism patients to prevent target organ damage, irrespective of blood pressure control or serum potassium levels. Triggered when a clinician encounters a PA patient with well‑controlled BP and normal K and wonders, 'Do I still need to treat with MRA?' or considers stopping therapy.

Recommends that diet, exercise, and behavioral modification be included in all obesity management approaches for patients with a BMI of 25 kg/m2 or higher. Triggered when clinicians ask, 'What foundational non-pharmacologic therapy should I start for this overweight patient?' or 'Should I initiate lifestyle changes for a patient with BMI 26?'.

Recommends ACE inhibitors, ARBs, or calcium channel blockers as first-line hypertension therapy rather than β‑adrenergic blockers in obese patients with type 2 diabetes. Triggers include when a clinician asks, 'What antihypertensive should I start for this obese patient with T2DM to avoid weight gain?' or 'Should I avoid β‑blockers in this patient with diabetes and hypertension?'

Establishes age- and gender-specific blood pressure goals for pediatric patients with primary aldosteronism (PA) using published normative data to assess treatment adequacy and avoid over-treatment. Use when managing hypertension in children with PA to evaluate if BP is adequately controlled; triggers include pediatric PA hypertension, BP not normalized with glucocorticoid therapy, and need for age‑specific BP targets.

Decide whether a newly-diagnosed multiple myeloma (NDMM) patient is eligible for high-dose melphalan + autologous stem cell transplantation (ASCT) as part of front-line therapy, using the EHA-ESMO 2021 criteria. Trigger when a clinician asks "is this myeloma patient fit for transplant", "ASCT eligibility for myeloma", "transplant-eligible NDMM", "should I refer for stem cell transplant", "high-dose melphalan candidate", or any decision about whether a newly-diagnosed myeloma patient should go to upfront ASCT.

This skill suggests using approved weight‑loss medication over no pharmacological therapy to ameliorate comorbidities and improve physical activity in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one comorbid condition. It is triggered when a clinician asks, for example, 'Should I add medication to help maintain weight loss in this patient with BMI 31 and diabetes?' or 'Is pharmacotherapy appropriate for long‑term weight control in a patient with BMI 28 and hypertension?'.